Breaking News Instant updates and real-time market news.

LGND

Ligand

$97.32

-1.22 (-1.24%)

18:23
10/07/16
10/07
18:23
10/07/16
18:23

Ligand says Carnexiv approval milestone to be recognized in Q4

Ligand's previous outlook for third quarter revenue was approximately one-third of the projected total revenues for the second half of 2016 of $66M-$70M. The Carnexiv approval milestone had been anticipated for the third quarter and now will be recognized in the fourth quarter.

LGND Ligand
$97.32

-1.22 (-1.24%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
09/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Hold from Underperform at Jefferies with analyst Jason Gammel citing valuation and improving financial metrics. 2. DineEquity (DIN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Chris O'Cull saying the stock has reached a good entry point, while its risk/reward ratio is "compelling." 3. Gaming and Leisure Properties (GLPI) upgraded to Overweight at Morgan Stanley. 4. Aviva (AV) upgraded to Buy from Neutral at UBS with the firm saying the company is positioned to be the risk-adjusted dividend leader in the sector. 5. Ligand (LGND) upgraded to Hold from Sell at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
HCWC
10/05/16
NO CHANGE
Target $160
HCWC
Buy
Ligand price target raised to $160 from $146 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Ligand Pharmaceuticals to $160 citing three recent positive events, namely positive Phase II focal segmental glomerulosclerosis data from partner Retrophin, the beginning of a Phase II clinical trial with LGD-6972 for the treatment of type 2 diabetes and the licensing of several therapeutic programs to Seelos. Werther keeps a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

AZUL

Azul

$28.59

0.07 (0.25%)

08:12
09/21/17
09/21
08:12
09/21/17
08:12
Hot Stocks
Azul orders five Airbus A330-900neo aircraft for international flights »

Azul announced an order…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNRX

VolitionRx

$2.72

-0.03 (-1.09%)

08:12
09/21/17
09/21
08:12
09/21/17
08:12
Conference/Events
Microcap Club to hold a summit »

MicroCap Leadership…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

FNF

FNF Group

$48.30

-0.13 (-0.27%)

, FNFV

FNFV

$17.35

0.25 (1.46%)

08:11
09/21/17
09/21
08:11
09/21/17
08:11
Conference/Events
Stephens to hold a field trip »

Jacksonville Investor…

FNF

FNF Group

$48.30

-0.13 (-0.27%)

FNFV

FNFV

$17.35

0.25 (1.46%)

BKFS

Black Knight Financial

$44.00

-0.1 (-0.23%)

FIS

FIS

$92.80

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 27

    Sep

ITUS

ITUS

$1.93

0.0101 (0.53%)

08:10
09/21/17
09/21
08:10
09/21/17
08:10
Hot Stocks
ITUS provides update on cancer detection technology, new CAR-T initiative »

ITUS provides a corporate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$185.51

-0.17 (-0.09%)

08:10
09/21/17
09/21
08:10
09/21/17
08:10
Initiation
Netflix initiated  »

Netflix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    Oct

  • 22

    Oct

08:09
09/21/17
09/21
08:09
09/21/17
08:09
Conference/Events
Citigroup to hold a conference »

Asean Yield Focus…

SHO

Sunstone Hotel

$15.93

0.16 (1.01%)

08:08
09/21/17
09/21
08:08
09/21/17
08:08
Hot Stocks
Sunstone Hotel provides update on impact from Hurricanes Harvey Irma »

Sunstone Hotel provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$37.23

-2 (-5.10%)

08:07
09/21/17
09/21
08:07
09/21/17
08:07
Recommendations
L Brands analyst commentary  »

Victoria's Secret…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.74

0.62 (4.73%)

, NVDA

Nvidia

$185.84

-1.51 (-0.81%)

08:05
09/21/17
09/21
08:05
09/21/17
08:05
Recommendations
AMD, Nvidia, Tesla analyst commentary  »

Tesla shift to AMD from…

AMD

AMD

$13.74

0.62 (4.73%)

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ALNY

Alnylam

$113.84

38.8 (51.71%)

08:05
09/21/17
09/21
08:05
09/21/17
08:05
Recommendations
Alnylam analyst commentary  »

Alnylam data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
09/21/17
09/21
08:05
09/21/17
08:05
General news
Canada wholesale trade report preview »

Canada wholesale trade…

BHGE

Baker Hughes

$37.50

0.11 (0.29%)

08:04
09/21/17
09/21
08:04
09/21/17
08:04
Recommendations
Baker Hughes analyst commentary  »

Baker Hughes 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

SCG

Scana

$57.80

-0.41 (-0.70%)

08:04
09/21/17
09/21
08:04
09/21/17
08:04
Hot Stocks
Scana receives subpoena for documents relating to nuclear project »

Scana announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TANH

Tantech Holdings

$4.07

0.08 (2.01%)

08:03
09/21/17
09/21
08:03
09/21/17
08:03
Hot Stocks
Tantech Holdings awarded $20M in electric van and bus sales orders »

Tantech Holdings'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VR

Validus

$46.93

1.2 (2.62%)

08:03
09/21/17
09/21
08:03
09/21/17
08:03
Recommendations
Validus analyst commentary  »

Validus net exposure to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOLD

Audentes Therapeutics

$26.57

1.04 (4.07%)

08:02
09/21/17
09/21
08:02
09/21/17
08:02
Hot Stocks
Audentes Therapeutics doses first patient in ASPIRO trial »

Audentes Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELGX

Endologix

$4.29

-0.15 (-3.38%)

08:01
09/21/17
09/21
08:01
09/21/17
08:01
Hot Stocks
Endologix announces CE Mark approval for Nellix system »

Endologix announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$156.07

-2.66 (-1.68%)

08:00
09/21/17
09/21
08:00
09/21/17
08:00
Options
Apple call buyer realizes 32% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

08:00
09/21/17
09/21
08:00
09/21/17
08:00
General news
Treasury Market Outlook: bonds remain mostly weaker »

Treasury Market Outlook:…

NVDA

Nvidia

, TSLA

Tesla

07:58
09/21/17
09/21
07:58
09/21/17
07:58
Technical Analysis
Technical View: AMD trades up on report it is working with Tesla on AI chip »

In the pre-market the AMD…

NVDA

Nvidia

TSLA

Tesla

AMD

AMD

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

JAKK

JAKKS Pacific

$3.15

0.325 (11.50%)

07:56
09/21/17
09/21
07:56
09/21/17
07:56
Downgrade
JAKKS Pacific rating change  »

JAKKS Pacific downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCL

Royal Caribbean

$114.94

-2.98 (-2.53%)

07:56
09/21/17
09/21
07:56
09/21/17
07:56
Conference/Events
Royal Caribbean management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RMBS

Rambus

$13.35

-0.23 (-1.69%)

07:55
09/21/17
09/21
07:55
09/21/17
07:55
Conference/Events
Rambus to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Oct

MO

Altria Group

$61.22

-1.01 (-1.62%)

07:54
09/21/17
09/21
07:54
09/21/17
07:54
Recommendations
Altria Group analyst commentary  »

Altria cigarette price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCO

Moody's

$136.77

0.03 (0.02%)

07:50
09/21/17
09/21
07:50
09/21/17
07:50
Conference/Events
Moody's management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.